Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 12/2021

01-12-2021 | Alopecia | Clinical Image

Madarosis in acute Kawasaki disease—an uncustomary accompaniment

Authors: Pratap Kumar Patra, Aaqib Zaffar Banday, Ridhima Aggarwal, Ankur Kumar Jindal, Surjit Singh

Published in: Clinical Rheumatology | Issue 12/2021

Login to get access

Excerpt

Madarosis (i.e., loss of eyebrows or eyelashes) is an innocuous manifestation of a variety of systemic illnesses (for example, endocrinopathies, infections, genetic disorders) including autoimmune diseases like lupus and localized scleroderma [1]. Alopecia in acute KD, which is a rare manifestation and mostly limited to loss of scalp hair, may reflect the underlying autoimmune/inflammatory mechanisms involved in the disease pathogenesis [2‐4]. However, reports of madarosis in KD are lacking. Herein, we report a novel finding of madarosis in acute KD. …
Literature
1.
Kumar A, Karthikeyan K (2012) Madarosis: a marker of many maladies. Int J Trichology 4(1):3–18CrossRef
2.
Bayers S, Shulman ST, Paller AS (2013) Kawasaki disease: part I. Diagnosis, clinical features, and pathogenesis. J Am Acad Dermatol. 69(4):501.e1–11CrossRef
3.
Nabavizadeh SH, Safari M, Amin R (2006) Hair loss as a sign of Kawasaki disease. Iran J Allergy Asthma Immunol 5(4):199–200PubMed
4.
Krishnamurthy S, Chandrashekar L, Mondal N (2012) Kawasaki disease and alopecia areata: coincidence or a true association? Pediatr Dermatol 29(4):532–534CrossRef
5.
Jia X, Du X, Bie S, Li X, Bao Y, Jiang M (2020) What dose of aspirin should be used in the initial treatment of Kawasaki disease? A meta-analysis. Rheumatology (Oxford) 59(8):1826–1833CrossRef
Metadata
Title
Madarosis in acute Kawasaki disease—an uncustomary accompaniment
Authors
Pratap Kumar Patra
Aaqib Zaffar Banday
Ridhima Aggarwal
Ankur Kumar Jindal
Surjit Singh
Publication date
01-12-2021
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 12/2021
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-021-05882-6

Other articles of this Issue 12/2021

Clinical Rheumatology 12/2021 Go to the issue

Review Article

Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis

Review Article

Mechanisms of thrombosis in ANCA-associated vasculitis

Original Article

Peripheral microcirculatory abnormalities are associated with cardiovascular risk in systemic sclerosis: a nailfold video capillaroscopy study

Brief Report

Gastrointestinal involvement in IgA vasculitis: a single-center 11-year study on a cohort of 118 children

Original Article

Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA—a retrospective study of claims data from 2009 TO 2020

Original Article

Indications and diagnostic outcome of antineutrophil cytoplasmic antibody testing in hospital medicine: a pattern of over-screening
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits